{"title":"Transitions of care: Assessment of adherence to long-acting injectable antipsychotic treatment following discharge from inpatient psychiatry.","authors":"Charnae Ross, Katie S Adams, Ericka L Crouse","doi":"10.9740/mhc.2025.02.009","DOIUrl":null,"url":null,"abstract":"<p><p><b>Introduction:</b> Long-acting injectable antipsychotics (LAI-APs) are used in patients with chronic psychiatric disorders as a strategy to manage oral medication nonadherence. Inpatient LAI-AP administration may assist with transition to the outpatient setting. The study objective was to characterize receipt of the next LAI-AP injection as planned in the outpatient setting following administration during inpatient psychiatric hospitalization. <b>Methods:</b> Patients 18 years and older were eligible for inclusion if they received an LAI-AP while inpatient and provided consent to monitor their 90-day follow-up. The primary outcome determined the percentage of patients who received the same LAI-AP administered during their inpatient psychiatric admission at their initial visit post discharge. The secondary outcomes compared appropriate documentation of the LAI-AP follow-up plan, oral overlap, and early psychiatric rehospitalization rates. <b>Results:</b> Fifty-one patients were included. Twenty-nine patients (56.9%) followed up within the outpatient setting after discharge and received their next scheduled LAI-AP as planned. Twenty-two patients (43.1%) did not receive an LAI-AP injection following discharge, 15 of whom did not attend their initial follow-up appointment. Thirty-nine patients (76.5%) were newly initiated on LAI-AP therapy, 19 of whom received their next follow-up injection. <b>Discussion:</b> More than 40% of patients who received an LAI-AP inpatient did not follow up in the outpatient setting despite appropriate discharge planning. Patients more likely to receive follow-up LAI-AP were older, received a maintenance injection while inpatient, and had a scheduled follow-up appointment. Prior to inpatient administration of LAI-AP, multiple factors should be considered, including outpatient adherence, access, feasibility of outpatient continuation, and transition of care plan.</p>","PeriodicalId":101313,"journal":{"name":"The mental health clinician","volume":"15 1","pages":"9-16"},"PeriodicalIF":0.0000,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11835369/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The mental health clinician","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.9740/mhc.2025.02.009","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Long-acting injectable antipsychotics (LAI-APs) are used in patients with chronic psychiatric disorders as a strategy to manage oral medication nonadherence. Inpatient LAI-AP administration may assist with transition to the outpatient setting. The study objective was to characterize receipt of the next LAI-AP injection as planned in the outpatient setting following administration during inpatient psychiatric hospitalization. Methods: Patients 18 years and older were eligible for inclusion if they received an LAI-AP while inpatient and provided consent to monitor their 90-day follow-up. The primary outcome determined the percentage of patients who received the same LAI-AP administered during their inpatient psychiatric admission at their initial visit post discharge. The secondary outcomes compared appropriate documentation of the LAI-AP follow-up plan, oral overlap, and early psychiatric rehospitalization rates. Results: Fifty-one patients were included. Twenty-nine patients (56.9%) followed up within the outpatient setting after discharge and received their next scheduled LAI-AP as planned. Twenty-two patients (43.1%) did not receive an LAI-AP injection following discharge, 15 of whom did not attend their initial follow-up appointment. Thirty-nine patients (76.5%) were newly initiated on LAI-AP therapy, 19 of whom received their next follow-up injection. Discussion: More than 40% of patients who received an LAI-AP inpatient did not follow up in the outpatient setting despite appropriate discharge planning. Patients more likely to receive follow-up LAI-AP were older, received a maintenance injection while inpatient, and had a scheduled follow-up appointment. Prior to inpatient administration of LAI-AP, multiple factors should be considered, including outpatient adherence, access, feasibility of outpatient continuation, and transition of care plan.